ID   MM253c1-4CG
AC   CVCL_UM68
DR   cancercelllines; CVCL_UM68
DR   Wikidata; Q95990210
RX   PubMed=3756862;
CC   Selected for resistance to: ChEBI; CHEBI_4027; Cyclophosphamide (CP; Endoxan).
CC   Selected for resistance to: ChEBI; CHEBI_21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_UM66 ! MM253c1
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=3756862;
RA   Maynard K., Parsons P.G.;
RT   "Cross-sensitivity of methylating agents, hydroxyurea, and
RT   methotrexate in human tumor cells of the Mer- phenotype.";
RL   Cancer Res. 46:5009-5013(1986).
//